Preclinical Development Services

Exposure assessment in non-GLP PK studies is a critical part of candidate selection and candidate nomination drug development activities. Developers must increase the bioavailability power of their target formulations, especially if their molecule is poorly soluble, before moving into pivotal GLP toxicology studies. 

Without careful attention to these steps, there is a great risk of having costly delays and potentially failure at clinical stages.

Knowing that preclinical GLP studies is critical to moving into first-in-human clinical trials, Quotient Sciences can help you accurately reach your preclinical milestones and transition into clinical development without delays.

Nominated drug candidates entering preclinical studies often have sub-optimal properties. Complications in preclinical development including poor solubility and issues such as hygroscopicity, cohesive tendency, and inherent surface amorphicity can all prevent a therapy from achieving clinical success if not addressed and controlled as early as possible.

Our preclinical technology screening service leverages our decades of experience in designing successful, clinic-ready drug product formulations. 

We embrace the challenge presented by new drug candidates and understand how to design appropriate strategies that molecules successfully into early-phase trials. Working with you, we'll identify the developability risks with your molecule and steps to mitigate these factors, balancing risk vs. reward against your time and financial investment considerations.